According to new research only about 6 in 10 lung cancer patients in the United States receive the minimal lung cancer treatments recommended by the National Comprehensive Cancer Network guidelines. Likelihood of receiving minimal treatment is lowest for black patients and the elderly.
The results of the study were published in the Journal 'the Annals of the American Thoracic Society'.
In 'Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States,' Erik F. Blom, MD, and colleagues report that the likelihood of receiving minimal treatments is even lower for black patients and the elderly.
The researchers based their findings on an analysis of 441,812 lung cancer cases diagnosed between 2010-2014 in the National Cancer Database.
An alliance of leading cancer centres, the National Comprehensive Cancer Network has established clinical guidelines for treating both non-small cell lung cancer and small cell lung cancer. Together, the two types of lung cancer are the leading cause of cancer deaths in the U.S.
The guidelines account for the stage of the disease when diagnosed and recommend more aggressive treatment of lung cancer in its early stages.
Treatment for lung cancer includes surgery, chemotherapy, conventional radiotherapy and stereotactic body radiation therapy, a specialized and precise type of radiotherapy that delivers high doses of radiation to small, well-defined tumours. Depending on the type of lung cancer and its stage, the guidelines may recommend combinations of these therapies.
The researchers found that, among the patients in the database, 62.1 per cent received guideline-concordant treatment, 21.6 per cent received no treatment and the remainder received treatment that was less intensive than recommended. Conventional radiotherapy only was among the most common less-intensive-than recommended therapy across all stages of both cancers.
Those with advanced non-small cell lung cancer were the least likely to receive guideline-concordant treatment. The researchers stress the importance of communicating to patients that the benefits of cancer treatment for advanced diseases, such as chemotherapy, can extend beyond survival to quality of life and symptom control.
After adjusting for factors that might have biased results, black patients were only 78 per cent as likely to receive the minimum treatment compared to those who were white. Those aged 80 and older were only 12 per cent as likely to receive the minimum treatment compared to those under the age of 50.
Study limitations include the fact that the database included no information about patient preferences or whether they were too sick to receive more intensive cancer treatment.
"While these findings are very concerning, it has always been easier to identify disparities in care than it has been to understand why they persist," said study co-author Douglas Arenberg, MD, professor of medicine and a pulmonologist at the University of Michigan. "There may be good reasons why less intensive treatment is in fact medically appropriate. The National Cancer Database does not include that level of detail."
Still, Dr Blom said, awareness of which patient groups are at risk of receiving less treatment than recommended could be a first step towards creating targeted interventions to improve cancer care.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)